Researchers at the Technion–Israel Institute of Technology have developed a novel nanomedicine approach that inhibits aggressive triple-negative breast cancer without delivering drugs, antibodies, or chemotherapy. The study, published in ACS Nano, describes engineered nanoparticles called MPsomes that act as biological decoys, reshaping the tumor microenvironment by preventing tumor-supporting immune cells from aiding cancer growth. In preclinical mouse models, the nanoparticles accumulated around tumors and suppressed tumor growth with efficacy comparable to advanced immunotherapies. The treatment works through biological signals encoded on the nanoparticle surface rather than through the release of active pharmaceutical ingredients. The researchers also demonstrated a scalable manufacturing process and found no signs of toxicity in major organs. The findings suggest a new therapeutic paradigm in which nanomedicines exert anticancer effects through immune modulation rather than drug delivery.
